136 related articles for article (PubMed ID: 7726317)
1. Fluphenazine plasma levels, dosage, efficacy, and side effects.
Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
[TBL] [Abstract][Full Text] [Related]
2. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
[TBL] [Abstract][Full Text] [Related]
3. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
4. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
[TBL] [Abstract][Full Text] [Related]
5. Fluphenazine plasma levels and clinical response.
Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
7. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
Kane J; Quitkin F; Rifkin A; Klein DF
Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
[TBL] [Abstract][Full Text] [Related]
9. Acute dystonia during fixed-dose neuroleptic treatment.
Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
[TBL] [Abstract][Full Text] [Related]
10. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
[TBL] [Abstract][Full Text] [Related]
11. Delayed severe extrapyramidal disturbance following frequent depot phenothiazine administration.
Warner AM; Wyman SM
Am J Psychiatry; 1975 Jul; 132(7):743-5. PubMed ID: 1137022
[TBL] [Abstract][Full Text] [Related]
12. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
13. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
[No Abstract] [Full Text] [Related]
14. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
Marder SR; Van Putten T; Mintz J; Lebell M; McKenzie J; May PR
Arch Gen Psychiatry; 1987 Jun; 44(6):518-21. PubMed ID: 3555385
[TBL] [Abstract][Full Text] [Related]
15. Fluphenazine pharmacokinetics and therapeutic response.
Dysken MW; Javaid JI; Chang SS; Schaffer C; Shahid A; Davis JM
Psychopharmacology (Berl); 1981; 73(3):205-10. PubMed ID: 6787637
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
17. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
18. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
19. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
20. High vs standard dosage fluphenazine HCL in acute schizophrenia.
Donlon PT; Meadow A; Tupin JP; Wahba M
J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]